Actualités
Séminaires

Takahiro ITO

DEPARTMENT OF BIOSYSTEMS SCIENCE

Lab of Cell Fate Dynamics and Therapeutics

Kyoto University, Japan

"Metabolic regulation of cell fates in cancer"

host : Andrei Turtoï (IRCM)

Raphael J. Morscher

Pediatric Cancer Metabolism Laboratory, Children's Research Center,

University of Zurich, 8032 Zurich, Suisse

"Reprogramming neuroblastoma translation by diet-enhanced polyamine depletion"

hôte : Alexandre DAVID (IRCM)

Géraldine GENTRIC

Equipe "Stress et Cancer"

Unité CHIP (U830) - Institut Curie-Paris

"Role of metabolic reprogramming in cell plasticity upon chemotherapy in ovarian cancers"

hôte : Julie Pannequin (IGF)

Professeur Bruno SEGUI

Centre de Recherche en Cancérologie de Toulouse (CRCT), UMR Inserm-CNRS-Toulouse University

"TNF blockade with certolizumab, but not infliximab, improves efficacy of anti-PD-1 and anti-CTLA-4 combination in melanoma"

host: Laurent GROS (IRCM)

The combination of anti-PD-1 and anti-CTLA-4 boosts the anti-cancer immune response in patients with advanced melanoma. However, 60% of patients fail to respond or relapse early after induction, and 95% develop immune-related adverse events (irAEs) such as colitis, which can be treated with infliximab, a tumour necrosis factor-alpha inhibitor (TNFi). The impact of TNFi on immune and clinical responses remains to be elucidated. Here we provide evidence that TNF blockade can improve the response to the anti-PD-1 and anti-CTLA-4 combination not only in mice but also in patients enrolled in a phase 1b clinical trial (TICIMEL, NTC03293784). However, certolizumab, but not infliximab, strongly stimulates immune and therapeutic responses to ICI. Mechanistically, we have shown that the IgG1 Fc fragment of infliximab impairs the ability of TNF blockade to stimulate the efficacy of ICI therapy.